Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.

Tamami Okamoto, Sho ichi Yamagishi, Yosuke Inagaki, Shinjiro Amano, Kohachiro Koga, Riichiro Abe, Masayoshi Takeuchi, Shigeaki Ohno, Akihiko Yoshimura, Zenji Makita

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE)-overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.

Original languageEnglish
Pages (from-to)1928-1930
Number of pages3
JournalThe FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Volume16
Issue number14
Publication statusPublished - 2002 Dec
Externally publishedYes

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.'. Together they form a unique fingerprint.

  • Cite this

    Okamoto, T., Yamagishi, S. I., Inagaki, Y., Amano, S., Koga, K., Abe, R., Takeuchi, M., Ohno, S., Yoshimura, A., & Makita, Z. (2002). Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 16(14), 1928-1930.